SSL International plc

Venus, 1 Old Park Lane, Trafford Park, Urmston, Manchester, M41 7HA , UK
Telephone: +44 (0)8701 222 690
Fax: +44 (0)8701 222 696
WWW: http://www.ssl-international.com
Medical Information Direct Line: +44 (0)161 638 2027
Medical Information e-mail: medical.information@ssl-international.com
Customer Care direct line: +44 (0)161 638 2399
Medical Information Fax: +44 (0)161 615 8819

Summary of Product Characteristics last updated on the eMC: 10/05/2007
SPC Diocalm


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Diocalm Tablets


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Morphine Hydrochloride 0.395mg

Activated Attapulgite 312.5mg

Attapulgite 187.5mg

For excipients, see 6.1.


Go to top of the page
3. PHARMACEUTICAL FORM

Tablet.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the relief of occasional diarrhoea and its associated pain and discomfort.


Go to top of the page
4.2 Posology and method of administration

Directions for use:

The tablets should be chewed and then followed by a drink of water. As well as using Diocalm, it is important to replace body fluids lost during diarrhoea.

Recommended dose:

Adults and children aged 12 years and over: 2 tablets.

Children aged 6 to under 12 years: 1 tablet.

The recommended dose should be taken every two to four hours as required according to the severity of the symptoms.

Do not take more than six doses in 24 hours.

Not to be given to children under 6 years.

Elderly: as the adult dose.


Go to top of the page
4.3 Contraindications

Patients with impaired renal function.

Hypersensitivity to any of the ingredients.


Go to top of the page
4.4 Special warnings and precautions for use

Labelling:

Warning: Do not exceed the stated dose.

Keep out of reach of children.

If symptoms persist for more than 24 hours, consult your doctor.

As well as taking Diocalm, it is important to replace body fluids lost during diarrhoea.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None.


Go to top of the page
4.6 Pregnancy and lactation

There are no known contraindications to the use of the product during pregnancy and lactation, but as with all medicines caution should be exercised.


Go to top of the page
4.7 Effects on ability to drive and use machines

None.


Go to top of the page
4.8 Undesirable effects

None.


Go to top of the page
4.9 Overdose

Overdosage is considered a theoretical possibility but, in practice, not a significant hazard with the small level of morphine in the product (40 tablets contain 15.8mg of morphine hydrochloride, an analgesic dose). Larger doses would cause nausea, vomiting, constipation, drowsiness and confusion. Convulsions may occur in infants and children. Morphine dependence is not considered to be a likely problem with the low doses of morphine present in the product.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Morphine, combinations, ATC code: A07DA52

Morphine acts by antimotility and antisecretory mechanisms on the gastrointestinal tract and is used in the symptomatic treatment of diarrhoea.

Attapulgite and activated attapulgite are effective gastrointestinal adsorbents.


Go to top of the page
5.2 Pharmacokinetic properties

Morphine salts are absorbed from the gastrointestinal tract. Conjugation to morphine 3- and 6-glucoronides occurs in the liver. About 10% of a dose of morphine is excreted through the bile into the faeces and the remainder is excreted in the urine, mainly as conjugates.

Attapulgite and activated attapulgite have a local action in the gastrointestinal tract. They are insoluble and remain unabsorbed.


Go to top of the page
5.3 Preclinical safety data

Preclinical safety data on these active ingredients in the literature have not revealed any pertinent and conclusive findings which are of relevance to the recommended dosage and use of the product.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Icing Sugar

Paregoric Essence

Magnesium Stearate.


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

Three years.


Go to top of the page
6.4 Special precautions for storage

None.


Go to top of the page
6.5 Nature and contents of container

Blister strips made of PVC/PVDC coated plastic with aluminium foil backing. Each strip contains 10 tablets. Two or four strips are contained in a boxboard carton.


Go to top of the page
6.6 Special precautions for disposal and other handling

None.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

SSL International PLC. Venus, 1 Old Park Lane, Trafford Park, Manchester, M41 7HA.


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 17905/0048


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

31/01/06


Go to top of the page
10. DATE OF REVISION OF THE TEXT

23/01/07



More information about this product

Link to this document from your website: http://emc.medicines.org.uk/medicine/4560/SPC/Diocalm/


Active Ingredients/Generics

 
   morphine hydrochloride
   activated attapulgite
   attapulgite


© 2010 Datapharm Communications Ltd

Go to www.medicines.org.uk